Navigation Links
HemaQuest Pharmaceuticals Presents Promising Results in Sickle Cell Disease and Beta Thalassemia
Date:12/8/2009

NEW ORLEANS, Dec. 8 /PRNewswire/ -- HemaQuest Pharmaceuticals presented data from new preclinical studies and early results from clinical trials of its lead drug candidate, HQK-1001, in sickle cell disease and beta thalassemia at the annual meeting of the American Society of Hematology in New Orleans. The preclinical studies demonstrated that HQK-1001 could augment the activity of a range of therapeutic agents that have been used in the past to treat hemoglobin disorders. In addition, the first clinical trials have begun testing HQK-1001 in patients with sickle cell disease or beta thalassemia. In these two HemaQuest-sponsored clinical trials, patients are being treated with increasing doses to determine its safety and pharmacodynamic effects. The studies are ongoing, and have demonstrated that the drug has a strong safety profile with early evidence of fetal globin induction, the key pharmacodynamic marker of therapeutic activity for this agent.

HemaQuest Chief Scientific Officer and Vice President, Clinical Affairs, Susan Perrine, MD, said, "We are pleased with the early clinical findings in patients with sickle cell disease and beta thalassemia. The fetal globin induction observed in both of the clinical trials is important, given its key role in ameliorating these diseases. Furthermore, the new evidence of additive or synergistic effects of HQK-1001 with other potential therapeutics suggests the potential for HQK-1001 to become an important drug in the treatment of these serious anemias."

HemaQuest President and CEO Ronald Berenson, MD, said, "These clinical studies provide early evidence of the safety and potential therapeutic activity of HQK-1001 in patients with sickle cell disease and beta thalassemia. We look forward to the successful completion of these trials and future clinical studies to document the therapeutic effects of HQK-1001 in patients with these serious and life-threatening diseases."

ABOUT HQK-1001

HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine and licensed to the Company. These compounds, designated as Short Chain Fatty Acid Derivatives (SCFADs), have been shown to stimulate fetal globin expression and red blood cell production in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia. HQK-1001 is an orally administered SCFAD, which has shown an excellent safety profile and biologic effects on fetal globin induction and red blood cell production in the laboratory, relevant animal models, and in healthy human subjects in Phase 1 clinical trials. Additionally, the compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia.

ABOUT SICKLE CELL DISEASE AND BETA THALASSEMIA

Sickle cell disease is a genetic disorder affecting the beta globin chain of adult hemoglobin, which results in distorted, rigid sickle red blood cells, which block blood vessels, causing lack of oxygen to tissues, acute episodes of pain (pain crises), lung injury (acute chest syndrome), and strokes. Infections are common, and chronic damage occurs in many organs, including the spleen, bones, kidneys, lungs, brain, and eyes. The sole drug which is approved to treat the disease is a cancer chemotherapy drug, hydroxyurea. The lifespan of sickle cell patients is markedly reduced in the U.S., where there are approximately 75-80,000 patients.

Beta thalassemias are among the most common genetic blood disorders worldwide, in which patients are unable to produce normal amounts of the beta globin chain of adult hemoglobin, with consequent rapid destruction of red blood cells and their progenitors, and moderate to severe, transfusion-dependent anemia. The standard therapies are transplantation and red blood cell transfusions, which cause iron overload and vital organ damage, and must be treated with iron chelator drugs. The average reported survival of affected patients is less than 30 years in the U.S. today.

ABOUT HEMAQUEST PHARMACEUTICALS

HemaQuest Pharmaceuticals (www.HemaQuest.com), established in Massachusetts in late 2007, is a Seattle-based biopharmaceutical company focused on developing small molecule therapeutics based on its proprietary SCFAD technologies to treat hemoglobin diseases. HemaQuest is also developing a second therapy for viral-related hematologic malignancies. The company's investors include De Novo Ventures, Forward Ventures, and Lilly Ventures.


CONTACT:   Jerome Lyons, Office Manager   T: 206.826.9900
 jlyons@hemaquest.com

SOURCE HemaQuest Pharmaceuticals


'/>"/>
SOURCE HemaQuest Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
2. Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe
3. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
4. Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
5. China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
6. KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals
7. Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
9. Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
10. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
11. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
Breaking Biology News(10 mins):